CAS: 1116235-97-2; 2-((2-((1-(2-(Dimethylamino)Acetyl)-5-Methoxyindolin-6-yl)Amino)-7H-Pyrrolo[2,3-D]Pyrimidin-4-yl)Amino)-6-Fluoro-N-Methylbenzamide

上下游产品

2-({2-{[1-(N,N-dimethylglycyl)-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino}-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)-6-fluoro-N-methylbenzamide

2-({2-{[1-(N,N-Dimethylglycyl)-5-(Methyloxy)-2,3-Dihydro-1H-Indol-6-Yl]Amino}-7-[(4-Methylphenyl)Sulfonyl]-7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl}Amino)-6-Fluoro-N-Methylbenzamide置于氢氧化钾,水体系中,用 1,4-二氧六环 用作溶剂,化学反应 3.0H,以89%的收率获得2-[[2-[[1-[(二甲基氨基)乙酰基]-5-(甲氧基)-2,3-二氢-1H-吲哚-6-基]氨基]-7H-吡咯并[2,3-D]嘧啶-4-基]氨基]-6-氟-N-甲基苯甲酰胺
参考文献: 2-[ (2-{phenylamino}-1H-Pyrrolo [2,3-D] Pyrimidin-4-yl) Amino] Benzamide Derivatives As Igf-1R Inhibitors For The Treatment Of Cancer[fr] Dérivés De 2-[(2-{phénylamino}-1H-Pyrrolo[2,3-D]Pyrimidin-4-yl)Amino]Benzamide En Tant Qu'Inhibiteur D'Igf-1R Pour Le Traitement Du Cancer
标题: 2-[ (2-{phenylamino}-1H-Pyrrolo [2,3-D] Pyrimidin-4-yl) Amino] Benzamide Derivatives As Igf-1R Inhibitors For The Treatment Of Cancer[fr] Dérivés De 2-[(2-{phénylamino}-1H-Pyrrolo[2,3-D]Pyrimidin-4-yl)Amino]Benzamide En Tant Qu'Inhibiteur D'Igf-1R Pour Le Traitement Du Cancer
摘要:新型吡咯吡嘧啶如公式(I)所示,及其药用可接受的衍生物.这些化合物在抑制igf-1R方面是有用的.

专利信息

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.